8-K: Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides Corporate Update

Nurix Therapeutics announced its third quarter fiscal 2024 financial results, highlighted by the expansion of clinical trials for NX-5948 and a strong cash position.

Summary

• Nurix Therapeutics reported a net loss of $49.0 million, or ($0.67) per share, for the third quarter ended August 31, 2024, compared to a net loss of $37.0 million, or ($0.68) per share, for the same period in 2023.
• Collaboration revenue decreased to $12.6 million from $18.5 million year-over-year, primarily due to the conclusion of the initial research term with Gilead, offset by increased revenue from the Pfizer collaboration.
• Research and development expenses increased to $55.5 million from $47.9 million year-over-year, driven by the acceleration of clinical trials for NX-5948, NX-2127, and NX-1607.
• The company's cash, cash equivalents, and marketable securities totaled $457.5 million as of August 31, 2024, up from $452.5 million as of May 31, 2024.
• Nurix initiated Phase 1b dose expansion of NX-5948 in chronic lymphocytic leukemia, Waldenstrom's macroglobulinemia, follicular lymphoma, and marginal zone lymphoma patients.
• Enrollment for NX-2127 in a Phase 1a/b trial was reinitiated with a new chirally controlled drug product.
• Preclinical data on Degrader-Antibody Conjugates (DACs) was presented, showcasing a new class of therapeutics.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the clinical progress and strong cash position, but tempered by increased losses and decreased collaboration revenue.

Positives

• The company has a strong cash position of $457.5 million.
• Clinical trials for NX-5948 are progressing with Phase 1b dose expansion initiated in multiple indications.
• Enrollment for NX-2127 has been reinitiated with a new drug product.
• Preclinical data for Degrader-Antibody Conjugates (DACs) shows promise for a new class of therapeutics.
• The company is on track to nominate a development candidate for the STAT6 degrader program with Sanofi.

Negatives

• Collaboration revenue decreased to $12.6 million from $18.5 million year-over-year.
• The company reported a net loss of $49.0 million for the quarter, an increase from the $37.0 million loss in the same period last year.
• Research and development expenses increased to $55.5 million from $47.9 million year-over-year.

Risks

• The company's future success depends on the ability to advance its drug candidates, obtain regulatory approvals, and commercialize its products.
• There are uncertainties related to the timing and results of preclinical studies and clinical trials.
• The company's ability to fund development activities and achieve development goals is subject to risk.
• The company is subject to risks related to the timing and receipt of payments from collaboration partners.
• Global business, political, and macroeconomic conditions could impact the company's business, clinical trials, financial condition, liquidity, and results of operations.

Future Outlook

Nurix anticipates clinical data readouts in the fourth quarter of 2024 and the initiation of pivotal studies of NX-5948 in 2025. They also expect to complete preclinical studies in 2024 to enable an IND application for NX-5948 in autoimmune indications.

Management Comments

• We continue to make great progress and remain focused on execution as we advance our pipeline of wholly owned and partnered programs in oncology, inflammation and immunology, said Arthur T. Sands, M.D., Ph.D., president and chief executive officer of Nurix.
• As we approach the end of the year, we are well capitalized and look forward to building further momentum as we head into clinical data readouts in the fourth quarter of 2024 and the initiation of pivotal studies of NX-5948 in 2025.

Industry Context

The announcement highlights Nurix's progress in the competitive biopharmaceutical space, particularly in targeted protein modulation for cancer and inflammatory diseases. The development of Degrader-Antibody Conjugates (DACs) positions Nurix as an innovator in the antibody-drug conjugate field.

Comparison to Industry Standards

• Nurix's focus on targeted protein degradation aligns with a growing trend in the biopharmaceutical industry, with companies like Arvinas and C4 Therapeutics also developing protein degraders.
• The initiation of Phase 1b trials for NX-5948 in multiple B-cell malignancies is comparable to other companies advancing novel therapies in these areas, such as AbbVie and BeiGene.
• The development of DACs is a novel approach, potentially offering advantages over traditional antibody-drug conjugates, which are being developed by companies like Seagen and ImmunoGen.
• Nurix's cash position of $457.5 million is relatively strong for a clinical-stage biotech company, providing runway for continued development.

Stakeholder Impact

• Shareholders may be concerned about the increased net loss, but encouraged by the clinical progress and strong cash position.
• Employees may be positively impacted by the company's continued growth and development.
• Patients may benefit from the potential development of new therapies for cancer and inflammatory diseases.
• Collaboration partners may be impacted by the company's progress and financial performance.

Next Steps

• Nurix plans to present additional clinical data from the NX-5948 study for patients with CLL by year-end 2024.
• Nurix will present a clinical update from the NX-5948 study on patients with WM at the 12th International Workshop on Waldenstroms Macroglobulinemia (IWWM 12) later this month.
• Nurix anticipates providing a program update for NX-1607 by year-end 2024.
• Nurix expects to complete ongoing preclinical studies in 2024 that can enable an investigational new drug (IND) application for NX-5948 in autoimmune indications.
• Future clinical updates for NX-2127 are anticipated in 2025.

Key Dates

Keywords

Nurix Therapeutics, NX-5948, NX-2127, NX-1607, Degrader-Antibody Conjugates, BTK degrader, Oncology, Clinical Trials, Financial Results, Biopharmaceutical, E3 ligase, Protein Degradation, Collaboration, Gilead, Pfizer, Sanofi